read theCongregationLog.

Most AI initiatives in private equity portfolios never translate into EBITDA uplift. This article explains why value gets lost, how ROI fog forms, and what operating partners consistently underestimate.

Private equity has poured billions into MSP roll-ups over the last decade. The thesis is familiar: acquire strong regional operators, standardise operations, unlock scale, and expand margins. On paper, it works. In reality, most MSP platforms hit an invisible wall somewhere between acquisition #2 and #4.

Across private equity portfolios, the same conversation repeats itself. An AI pilot shows promise. A proof of concept is funded. Early results look encouraging. Then time passes.

AI fatigue is real. After years of webinars, “AI strategies,” and LinkedIn posts about ChatGPT, the reality is this: most SME and mid-cap AI projects still die in committee before they ever reach production. The problem isn’t the technology. It’s the theatre around it.

Every organisation has them: those expensive, persistent headaches that never seem to go away. Compliance hurdles that drain resources, clunky internal processes that frustrate staff, or customer service bottlenecks that quietly bleed revenue.

Clinical trials are the backbone of medical innovation. Every new drug, therapy, or medical device must pass rigorous testing before it reaches patients. Yet the process is notoriously slow and expensive: the average clinical trial can take 6–7 years and cost hundreds of millions of pounds.

Healthcare is one of the hardest industries to disrupt — and one of the most rewarding. For entrepreneurs, the stakes are high: build the right product, and you don’t just create a profitable business, you **change lives**. From biotech breakthroughs to digital therapeutics, the intersection of health and innovation is full of opportunity — but also full of pitfalls.

Technology is moving faster than ever. Artificial Intelligence is reshaping industries. Extended Reality is redefining training and customer engagement. Web3 and decentralised systems are challenging traditional models of ownership and interaction.

Healthcare has always been an arena of rapid innovation. From the discovery of antibiotics to the first MRI scanner, each leap has changed how we diagnose, treat, and live. Yet what we’re witnessing today is not just another incremental step forward. It is a wholesale shift — from a system built on pills and procedures to one increasingly defined by pixels, platforms, and personalised digital experiences.